Revolutionizing Ovarian Cancer Therapy by Drug Repositioning for Accelerated and Cost-effective Treatments

Overview

Journal Front Oncol

Date 2025 Jan 29

PMID 39876896

Authors

Edgar Yebran Villegas-Vazquez

Francisco Pavel Marin-Carrasco

Octavio Daniel Reyes-Hernandez

Andrea S Baez-Gonzalez

Lilia Patricia Bustamante-Montes

Teresita Padilla-Benavides

Laura Itzel Quintas-Granados

Gabriela Figueroa-Gonzalez

Affiliations

Soon will be listed here.

Abstract

Drug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow. This review focuses on drug repositioning for ovarian cancer treatment, showcasing a comprehensive exploration grounded in thorough experiments across diverse cancer cell lines, which are validated through preclinical models. These insights not only shed light on the efficacy of these drugs but also expand in potential synergies with other pharmaceutical agents, favoring the development of cost-effective treatments for cancer patients.

References

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5):672-705. DOI: 10.1093/annonc/mdz062. View

Zhou Y, Xia J, Xu S, She T, Zhang Y, Sun Y . Experimental mouse models for translational human cancer research. Front Immunol. 2023; 14:1095388. PMC: 10036357. DOI: 10.3389/fimmu.2023.1095388. View

Elez M, Tabernero J, Geary D, Macarulla T, Kang S, Kahatt C . First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res. 2014; 20(8):2205-14. DOI: 10.1158/1078-0432.CCR-13-1880. View

Ayyagari V, Johnston N, Brard L . Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer. Anticancer Drugs. 2016; 27(6):547-59. PMC: 5053334. DOI: 10.1097/CAD.0000000000000364. View

Kumar S, Rajkumar S . Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006; 42(11):1612-22. DOI: 10.1016/j.ejca.2006.04.004. View

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

Malanga G, Wolff E . Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics. Spine J. 2008; 8(1):173-84. DOI: 10.1016/j.spinee.2007.10.013. View

Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R . Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012; 13(9):946-56. PMC: 3431503. DOI: 10.1016/S1470-2045(12)70322-4. View

Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M . Correction: YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients. PLoS One. 2016; 11(3):e0152712. PMC: 4807839. DOI: 10.1371/journal.pone.0152712. View

10.

Kodama M, Kodama T, Newberg J, Katayama H, Kobayashi M, Hanash S . In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2017; 114(35):E7301-E7310. PMC: 5584430. DOI: 10.1073/pnas.1705441114. View

11.

Iida Y, Okamoto A, Hollis R, Gourley C, Herrington C . Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. 2020; 31(4):605-616. DOI: 10.1136/ijgc-2020-001656. View

12.

Silverman L, Demakos E, Peterson B, Kornblith A, Holland J, Odchimar-Reissig R . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20(10):2429-40. DOI: 10.1200/JCO.2002.04.117. View

13.

Drinberg V, Bitcover R, Rajchenbach W, Peer D . Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. Cancer Lett. 2014; 354(2):290-8. DOI: 10.1016/j.canlet.2014.08.026. View

14.

Singh S, Jaigirdar A, Mulkey F, Cheng J, Hamed S, Li Y . FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer. Clin Cancer Res. 2020; 27(9):2378-2382. PMC: 9532454. DOI: 10.1158/1078-0432.CCR-20-3901. View

15.

Markham A . Lurbinectedin: First Approval. Drugs. 2020; 80(13):1345-1353. DOI: 10.1007/s40265-020-01374-0. View

16.

Beral V, Bull D, Green J, Reeves G . Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007; 369(9574):1703-10. DOI: 10.1016/S0140-6736(07)60534-0. View

17.

Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J . Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer. 2004; 109(6):833-8. DOI: 10.1002/ijc.20022. View

18.

Vasey P, Jayson G, Gordon A, Gabra H, Coleman R, Atkinson R . Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96(22):1682-91. DOI: 10.1093/jnci/djh323. View

19.

Major P, Coleman R . Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol. 2001; 28(2 Suppl 6):17-24. DOI: 10.1016/s0093-7754(01)90261-1. View

20.

Arora N, Talhouk A, McAlpine J, Law M, Hanley G . Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. BMC Cancer. 2018; 18(1):1039. PMC: 6202883. DOI: 10.1186/s12885-018-4970-9. View